explore -WSS

explore

author：knowledge 2025-09-30 19:26:00 - browse：9176

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Medicare drug price negotiation continues, as pharma counteroffers

WSS

Gene therapy denied for Afghan refugee whose father aided U.S.

Hospital chaplains balance Covid safety with patients’ spiritual needs

Readout Newsletter: BridgeBio, Akero, and human embryo models

FDA early review: GLP

Medicare Advantage overpayments discussion gets experts fired up

For AI in health care standards, federal regulators join with industry group

entertainment

explore

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

Families look for replacement for GSK asthma drug Flovent

Heart attack and stroke risk calculators need revising

Why Talkspace is targeting Medicare, a tricky market

Malaria cases in Florida and Texas: Here’s what you need to know

JPM pitch from hospitals? Revenue streams outside of patient care

What does generative AI mean for health care? We asked experts

Lack of health data on LGBTQ+ people has serious consequences

Apple is now the first public company to be valued at $3 trillion

At JPM 2024, hospital systems pitch financial strength to investors

explore

Lack of health data on LGBTQ+ people has serious consequences

Lack of health data on LGBTQ+ people has serious consequences

For AI in health care standards, federal regulators join with industry group

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Families look for replacement for GSK asthma drug Flovent

Harvard's David Sinclair gets blowback over aging

hotspot

focus

leisure time

hotspot